Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges.

Bogoyevitch MA, Ngoei KR, Zhao TT, Yeap YY, Ng DC.

Biochim Biophys Acta. 2010 Mar;1804(3):463-75. doi: 10.1016/j.bbapap.2009.11.002. Review.

PMID:
19900593
2.

JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities.

Mehan S, Meena H, Sharma D, Sankhla R.

J Mol Neurosci. 2011 Mar;43(3):376-90. doi: 10.1007/s12031-010-9454-6. Review.

PMID:
20878262
3.

Inhibitors of c-Jun N-terminal kinases: an update.

Koch P, Gehringer M, Laufer SA.

J Med Chem. 2015 Jan 8;58(1):72-95. doi: 10.1021/jm501212r. Review.

PMID:
25415535
4.

Inhibitors of c-Jun N-terminal kinases: JuNK no more?

Bogoyevitch MA, Arthur PG.

Biochim Biophys Acta. 2008 Jan;1784(1):76-93. Review.

PMID:
17964301
5.

c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).

Gehringer M, Muth F, Koch P, Laufer SA.

Expert Opin Ther Pat. 2015;25(8):849-72. doi: 10.1517/13543776.2015.1039984. Review.

PMID:
25991433
6.
7.

The c-jun kinase/stress-activated pathway: regulation, function and role in human disease.

Johnson GL, Nakamura K.

Biochim Biophys Acta. 2007 Aug;1773(8):1341-8. Review.

8.

JNK signalling: a possible target to prevent neurodegeneration.

Borsello T, Forloni G.

Curr Pharm Des. 2007;13(18):1875-86. Review.

PMID:
17584114
9.

Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticancer agents.

Messoussi A, Feneyrolles C, Bros A, Deroide A, Daydé-Cazals B, Chevé G, Van Hijfte N, Fauvel B, Bougrin K, Yasri A.

Chem Biol. 2014 Nov 20;21(11):1433-43. doi: 10.1016/j.chembiol.2014.09.007. Review.

10.
11.

JNK pathway signaling: a novel and smarter therapeutic targets for various biological diseases.

Kumar A, Singh UK, Kini SG, Garg V, Agrawal S, Tomar PK, Pathak P, Chaudhary A, Gupta P, Malik A.

Future Med Chem. 2015;7(15):2065-86. doi: 10.4155/fmc.15.132. Review.

PMID:
26505831
12.

Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential.

Bogoyevitch MA, Boehm I, Oakley A, Ketterman AJ, Barr RK.

Biochim Biophys Acta. 2004 Mar 11;1697(1-2):89-101. Review.

PMID:
15023353
13.

From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance.

Karin M, Gallagher E.

IUBMB Life. 2005 Apr-May;57(4-5):283-95. Review.

14.

The JNK signal transduction pathway.

Weston CR, Davis RJ.

Curr Opin Cell Biol. 2007 Apr;19(2):142-9. Review.

PMID:
17303404
15.

Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity.

Hahmann C, Schroeter T.

Cell Mol Life Sci. 2010 Jan;67(2):171-7. doi: 10.1007/s00018-009-0189-x. Review.

PMID:
19907920
16.

A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches.

Seki E, Brenner DA, Karin M.

Gastroenterology. 2012 Aug;143(2):307-20. doi: 10.1053/j.gastro.2012.06.004. Review.

17.

Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage.

Waetzig V, Herdegen T.

Trends Pharmacol Sci. 2005 Sep;26(9):455-61. Review.

PMID:
16054242
18.

JNK3 as a therapeutic target for neurodegenerative diseases.

Antoniou X, Falconi M, Di Marino D, Borsello T.

J Alzheimers Dis. 2011;24(4):633-42. doi: 10.3233/JAD-2011-091567. Review.

PMID:
21321401
19.

JNK regulation of oncogenesis.

Heasley LE, Han SY.

Mol Cells. 2006 Apr 30;21(2):167-73. Review.

20.

Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases.

Bogoyevitch MA, Kobe B.

Microbiol Mol Biol Rev. 2006 Dec;70(4):1061-95. Review.

Items per page

Supplemental Content

Support Center